Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.

Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.

Abstract: This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.

Abstract: Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.

Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Abstract: The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.

Abstract: A prosthesis comprising a water-dissolvable coating. A prosthesis for a lacrimal canaliculus comprising a swellable punctal plug with a proximal end and a distal end, with the plug comprising a water-dissolvable biocompatible coating on the distal and/or the proximal end. Materials and methods for making and using the same. A prosthesis for placement in or across natural or prosthetic lumens, ostia, ducts, sinus, or sphincters, the prosthesis comprising a coating. The prosthesis can further provide a depot for sustained drug delivery to tissue.

Abstract: Provided herein are sustained release biodegradable ocular hydrogel implants which are useful for lowering ocular pressure and for treating related conditions.

Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.

Abstract: A prosthesis comprising a water-dissolvable coating. A prosthesis for a lacrimal canaliculus comprising a swellable punctal plug with a proximal end and a distal end, with the plug comprising a water-dissolvable biocompatible coating on the distal and/or the proximal end. Materials and methods for making and using the same. A prosthesis for placement in or across natural or prosthetic lumens, ostia, ducts, sinus, or sphincters, the prosthesis comprising a coating. The prosthesis can further provide a depot for sustained drug delivery to tissue.

Abstract: Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Abstract: A prosthesis comprising a water-dissolvable coating. A prosthesis for a lacrimal canaliculus comprising a swellable punctal plug with a proximal end and a distal end, with the plug comprising a water-dissolvable biocompatible coating on the distal and/or the proximal end. Materials and methods for making and using the same. A prosthesis for placement in or across natural or prosthetic lumens, ostia, ducts, sinus, or sphincters, the prosthesis comprising a coating. The prosthesis can further provide a depot for sustained drug delivery to tissue.

Abstract: Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form.

Abstract: Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form.

Abstract: An applicator assembly for mixing at least a first and second component is provided. The applicator assembly includes a manifold configured for operable engagement with at least a first and second source of component, the manifold including at least a first and second component channel therethrough, an elongated shaft extending distally from the manifold, the elongated shaft including at least a first and second component lumen extending the length thereof, the at least first and second component channels in fluid communication with the at least first and second component channels, a tip assembly defining a first chamber, an intermediate chamber and a final chamber.